GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 380
- Registration Number
- NCT00197080
- Locations
- 🇨🇦
GSK Investigational Site, Regina, Saskatchewan, Canada
Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects
- Conditions
- HIV Infection
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00197197
- Locations
- 🇧🇪
GSK Investigational Site, Bruxelles, Belgium
Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine
- Conditions
- Influenza
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6213
- Registration Number
- NCT00197223
- Locations
- 🇨🇿
GSK Investigational Site, Hradec Kralove, Czech Republic
A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10708
- Registration Number
- NCT00197210
- Locations
- 🇸🇬
GSK Investigational Site, Singapore, Singapore
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Conjugated meningococcal ACWY-TT (vaccine)Biological: DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)Biological: DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)Biological: Meningitec™Biological: Mencevax™ACWY
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 461
- Registration Number
- NCT00196976
- Locations
- 🇬🇷
GSK Investigational Site, Tripolis, Greece
Study In People With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 448
- Registration Number
- NCT00196989
- Locations
- 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation
Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years
- Conditions
- Hepatitis BHepatitis A
- Interventions
- Biological: Twinrix™ AdultBiological: Twinrix™ Junior
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 244
- Registration Number
- NCT00197119
- Locations
- 🇨🇿
GSK Investigational Site, Hradec Kralove, Czech Republic
Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region
- Conditions
- Malaria
- Interventions
- Biological: RTS,S/AS02DBiological: Engerix-B®Biological: TETRActHib™
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 214
- Registration Number
- NCT00197028
- Locations
- 🇲🇿
GSK Investigational Site, Maputo, Mozambique
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)
- Conditions
- Rhinitis, Allergic, Seasonal
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT00197262
- Locations
- 🇺🇸
GSK Investigational Site, West Allis, Wisconsin, United States
A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.
- Conditions
- Malaria
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2022
- Registration Number
- NCT00197041
- Locations
- 🇲🇿
GSK Investigational Site, Maputo, Mozambique